World's Best Scientists 2026 revealed!
Kah Whye Peng

Kah Whye Peng

D-Index & Metrics

Microbiology

D-Index
66
Citations
11611
World Ranking
2454
National Ranking
993

Kah Whye Peng publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Kah Whye Peng sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 198 publications — 48th percentile

48% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Kah Whye Peng D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Kah Whye Peng sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 66 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Kah Whye Peng is affiliated with the Mayo Clinic in the United States and has contributed extensively to research in the fields of medicine and biochemistry, genetics, and molecular biology. Their work spans various subfields, including genetics, epidemiology, surgery, oncology, and infectious diseases.

The scientist's research predominantly focuses on virus-based gene therapy, particularly with applications in oncology and infectious disease treatments. Their contributions also include significant work on CAR-T cell therapy, bladder and urothelial cancer treatments, urological disorders, and viral infectious diseases including cytomegalovirus and herpesvirus infections.

Peng has published in multiple venues, with frequent appearances in the Journal of Clinical Oncology, Molecular Cancer Therapeutics, Molecular Therapy, Cancer Research, and Blood Advances.

Notable recent papers authored or coauthored by Kah Whye Peng include:

  • "Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma" (2022, Blood Advances)
  • "IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers" (2021, mSphere)
  • "Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients" (2020, Molecular Cancer Therapeutics)
  • "Preclinical Safety Assessment of MV-s-NAP, a Novel Oncolytic Measles Virus Strain Armed with an H. pylori Immunostimulatory Bacterial Transgene" (2022, Molecular Therapy - Methods & Clinical Development)
  • "Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers" (2020, Molecular Therapy - Oncolytics)

Kah Whye Peng collaborates regularly with several researchers, with frequent coauthors including:

  • Stephen J. Russell
  • Alice Bexon
  • Nandakumar Packiriswamy
  • Shruthi Naik
  • Lianwen Zhang

The combination of Peng's publication history and coauthorships suggests a multidisciplinary approach integrating clinical oncology, molecular virology, and immunology. Their work on oncolytic viruses and gene therapy further integrates advanced molecular therapies with clinical applications.

Best Publications

  • High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.

    Bambi D. Anderson;Takafumi Nakamura;Stephen J. Russell;Kah Whye Peng

  • Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

    David Dingli;Kah Whye Peng;Mary E. Harvey;Philip R. Greipp

  • Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer

    Evanthia Galanis;Lynn C. Hartmann;William A. Cliby;Harry J. Long

  • Rescue and propagation of fully retargeted oncolytic measles viruses.

    Takafumi Nakamura;Kah Whye Peng;Mary Harvey;Suzanne Greiner

  • Use of a Vaccine Strain of Measles Virus Genetically Engineered to Produce Carcinoembryonic Antigen as a Novel Therapeutic Agent against Glioblastoma Multiforme

    Loi K. Phuong;Cory Allen;Kah Whye Peng;Caterina Giannini

  • Intraperitoneal Therapy of Ovarian Cancer Using an Engineered Measles Virus

    Kah Whye Peng;Cynthia J. TenEyck;Evanthia Galanis;Kimberly R. Kalli

  • Viruses as anticancer drugs

    Stephen J. Russell;Kah Whye Peng

  • Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model

    Emily K. Mader;Yoshihiro Maeyama;Yi Lin;Greg W. Butler

  • Measles virus for cancer therapy.

    Stephen J. Russell;Kah Whye Peng

  • Systemic therapy of myeloma xenografts by an attenuated measles virus

    Kah Whye Peng;Gregory J. Ahmann;Linh Pham;Philip R. Greipp

  • Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides.

    Kah Whye Peng;Suzanne Facteau;Troy Wegman;Dennis O'Kane

  • Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.

    Kah Whye Peng;Kah Whye Peng;Kathleen A. Donovan;Kathleen A. Donovan;Urs Schneider;Urs Schneider;Roberto Cattaneo;Roberto Cattaneo

  • Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer

    Evanthia Galanis;Pamela J. Atherton;Matthew J. Maurer;Keith L Knutson

  • Designing and building oncolytic viruses.

    Justin Maroun;Miguel Muñoz-Alía;Arun Ammayappan;Autumn Schulze

  • Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide

    Myers Rm;Greiner Sm;Harvey Me;Griesmann G

  • Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.

    Ong Ht;Hasegawa K;Dietz Ab;Russell Sj

  • Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.

    Angela Dispenzieri;Caili Tong;Betsy LaPlant;Martha Q. Lacy

  • Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia

    Weiwei Shen;Mrinal M. Patnaik;Autumn Ruiz;Stephen J. Russell

  • Oncolytic measles virus targets high CD46 expression on multiple myeloma cells

    Hooi Tin Ong;Michael M. Timm;Philip R. Greipp;Thomas E. Witzig

  • Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer

    Emily K. Mader;Greg Butler;Sean C. Dowdy;Andrea Mariani

  • A gene delivery system activatable by disease-associated matrix metalloproteinases.

    Kah Whye Peng;Frances J. Morling;François Loic Cosset;Gillian Murphy

  • Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma

    Boris Blechacz;Patrick L. Splinter;Suzanne Greiner;Rae Myers

Frequent Co-Authors

Evanthia Galanis
Evanthia Galanis Mayo Clinic
Roberto Cattaneo
Roberto Cattaneo Mayo Clinic
François-Loïc Cosset
François-Loïc Cosset Claude Bernard University Lyon 1
Glen N. Barber
Glen N. Barber University of Miami
David Dingli
David Dingli Mayo Clinic
Yasuhiro Ikeda
Yasuhiro Ikeda AstraZeneca (United Kingdom)
Martha Q. Lacy
Martha Q. Lacy Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in microbiology, exploring related fields can broaden career opportunities. Programs such as online health information management degree programs cahiim accredited provide valuable knowledge in managing health data effectively, a skill increasingly important in healthcare settings.

Those seeking a faster entry into the healthcare workforce might consider an accelerated medical billing and coding certificate online. This pathway offers a streamlined approach to gaining certification and can complement microbiology expertise for roles involving medical data and coding.

Exploring online healthcare degrees that pay well can help students align their interests with financially rewarding careers. Many online programs offer flexibility and access to in-demand professions, making it easier to integrate studies with existing commitments.

Additionally, an MPH (Master of Public Health) can enhance career options, especially in research and public health fields. For those concerned about admission selectivity, reviewing easy admission online mph programs can provide practical entry points into advanced public health education.

Best Scientists Citing Kah Whye Peng

Trending Scientists

Recently Published Articles